Operator: Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
A relatively new method of heart transplantation, which allows for the use of hearts donated after circulatory death could expand the pool of available donor hearts by a projected 30%. Here's what's happening.
5,000 Patients Treated Globally The versatility and innovation of Abiomed's (NASDAQ: ABMD) Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption
5,000 Patients Treated GloballyDANVERS, Mass. (BUSINESS WIRE) The versatility and innovation of Abiomed’s (NASDAQ: ABMD) Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the world. Today, Abiomed announce.